The IMCAS World Congress 2026, held in Paris from January 29 to 31, 2026, once again established itself as the most influential international meeting in dermatology, plastic surgery, and aesthetic and regenerative medicine. Over three days, the congress brought together more than 20,000 attendees, 950 international speakers, over 310 hours of scientific learning, 370 exhibitions, and representation from 130 countries, confirming its role as the global stage where trends shaping the future of the industry are defined.
Within this high-level scientific and international context, GlobalSkin Laboratoire had a strong presence with the presentation of its SeduSkin line, reaffirming its commitment to innovation, applied research, and the development of advanced solutions for skin care and regeneration.blog
Within this high-level scientific and international context, GlobalSkin Laboratoire had a strong presence with the presentation of its SeduSkin line, reaffirming its commitment to innovation, applied research, and the development of advanced solutions for skin care and regeneration.
SeduSkin at IMCAS 2026: scientific innovation with a regenerative focus
Throughout the congress, GlobalSkin Laboratoire presented its SeduSkin portfolio in an environment aligned with the key themes addressed at IMCAS 2026, including regenerative medicine, combination treatments, facial harmonization, skin aging, procedural safety, and the integration of new technologies into clinical practice.
Within this proposal, GlobalSkin Laboratoire highlighted key solutions from its SeduSkin portfolio, including the HYLAS line, designed for deep hydration protocols, cellular regeneration, and overall improvement of skin quality; LIPAX, a lipolytic agent developed for the medical management of localized adiposity within advanced aesthetic protocols; and EVOLUTION, a super skinbooster designed to enhance skin regeneration, improve texture, luminosity, and firmness, as well as optimize outcomes in combination treatments.
These solutions were presented within a scientific framework that explored topics such as applied anatomy, complication management, the use of diagnostic imaging, artificial intelligence in aesthetic medicine, and emerging strategies in regenerative medicine.
Global launch of EXO FOLIX and EXO++ at IMCAS World Congress 2026
One of the most significant moments of GlobalSkin Laboratoire’s participation at IMCAS 2026 was the presentation of its exosome line: EXO FOLIX and EXO++.
This launch positioned the company at the forefront of advanced regenerative medicine, during a congress where exosomes, biotechnology, and approaches focused on longevity and cellular stimulation were central to multiple scientific sessions.
The introduction of EXO FOLIX and EXO++ generated strong interest among dermatologists, aesthetic physicians, plastic surgeons, and researchers, further consolidating GlobalSkin Laboratoire as a key player in the development of solutions based on tissue regeneration, cellular repair, and biomedical technology applied to aesthetics.
GlobalSkin Laboratoire and its future vision in aesthetic medicine
GlobalSkin Laboratoire’s participation in IMCAS World Congress 2026 represented a strategic step in strengthening its international positioning. The presentation of the SeduSkin line, together with the global launch of EXO FOLIX and EXO++, reinforced its commitment to a comprehensive vision of aesthetic medicine, where science, technological innovation, and clinical practice converge to deliver safe, effective solutions aligned with the evolving demands of the industry.
IMCAS 2026 was once again the meeting point where the future of aesthetic, dermatological, and regenerative medicine is shaped, and GlobalSkin Laboratoire was an active part of this global stage that drives the evolution and excellence of the industry. See you in 2027.
